These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8411102)

  • 1. Immunisation of macaques with SIV env recombinants: specificity of T cell and antibody responses and evaluation of protective efficacy.
    Mills KH; Page M; Kitchin P; Chan L; Jones W; Silvera P; Corcoran T; Flanagan B; Ling C; Thiriart C
    J Med Primatol; 1993; 22(2-3):104-9. PubMed ID: 8411102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins.
    Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P
    J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160.
    Hu SL; Stallard V; Abrams K; Barber GN; Kuller L; Langlois AJ; Morton WR; Benveniste RE
    J Med Primatol; 1993; 22(2-3):92-9. PubMed ID: 8411113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques.
    Torres JV; Anderson DE; Malley A; Banapour B; Axthelm MK; Benjamini E; Gardner MB
    J Med Primatol; 1993; 22(2-3):129-37. PubMed ID: 7692056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simian immunodeficiency virus-specific cytotoxic T lymphocytes in rhesus monkeys: characterization and vaccine induction.
    Letvin NL; Miller MD; Shen L; Chen ZW; Yasutomi Y
    Semin Immunol; 1993 Jun; 5(3):215-23. PubMed ID: 8394161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIV vaccine protection of rhesus monkeys.
    Gardner MB; Carlson JR; Jennings M; Rosenthal A; Langlois A; Haynes B; Bolognesi D; Palker TJ
    Biotechnol Ther; 1991; 2(1-2):9-19. PubMed ID: 1845125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells.
    Putkonen P; Nilsson C; Hild K; Benthin R; Cranage M; Aubertin AM; Biberfeld G
    J Med Primatol; 1993; 22(2-3):100-3. PubMed ID: 8411101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130.
    Voss G; Dittmer U; Coulibaly C; Makoschey B; Petry H; Lüke W; Hunsmann G
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1757-63. PubMed ID: 8376957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses.
    Kent SJ; Stallard V; Corey L; Hu SL; Morton WR; Gritz L; Panicali DL; Greenberg PD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):551-60. PubMed ID: 7917517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of the intracytoplasmic domain of the simian immunodeficiency virus (SIV) envelope glycoprotein for pathogenesis.
    Luciw PA; Shaw KE; Shacklett BL; Marthas ML
    Virology; 1998 Dec; 252(1):9-16. PubMed ID: 9875311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.
    Shacklett BL; Shaw KE; Adamson LA; Wilkens DT; Cox CA; Montefiori DC; Gardner MB; Sonigo P; Luciw PA
    J Virol; 2002 Nov; 76(22):11365-78. PubMed ID: 12388697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
    McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
    J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.
    Almond N; Jenkins A; Jones S; Arnold C; Silvera P; Kent K; Mills KHG; Stott EJ
    J Gen Virol; 1999 Sep; 80 ( Pt 9)():2375-2382. PubMed ID: 10501490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation.
    Torres JV; Malley A; Banapour B; Anderson DE; Axthelm MK; Gardner MB; Benjamini E
    AIDS Res Hum Retroviruses; 1993 May; 9(5):423-30. PubMed ID: 7686386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.